LIVIVO - Search results -

Search results

Result 1 - 10 of total 27

Search options

Article ; Conference proceedings: A RARE CASE OF BOWEL OBSTRUCTION

Zamora Nava, L.E. / Miranda-Zazueta, G.

2022 Volume 54, Issue S 01

Event/congress	ESGE Days 2022, Prague, Czech Republic, 2022-04-28
Language	English
Publishing date	2022-04-01
Publisher	Georg Thieme Verlag KG
Publishing place	Stuttgart ; New York
Document type	Article ; Conference proceedings
ZDB-ID	80120-3
ISSN	1438-8812 ; 0013-726X
ISSN (online)	1438-8812
ISSN	0013-726X
DOI	10.1055/s-0042-1745330
Database	Thieme publisher's database

In stock of ZB MED Cologne/Königswinter

Zs.A 669: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 162: Show issues

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article: The impact of different infectious complications on mortality of hospitalized patients with liver cirrhosis.

Díaz-Hernández, Héctor Adrián / Vázquez-Anaya, Gerardo / Miranda-Zazueta, Godolfino / Castro-Narro, Graciela Elia

Annals of hepatology

2020 Volume 19, Issue 4, Page(s) 427–436

Abstract: Introduction and objectives: Bacterial infections are common complications in patients with cirrhosis and are associated with poor prognosis. There are no studies that analyze the impact of different infectious complications in the mortality of these ... ...

Abstract	Introduction and objectives: Bacterial infections are common complications in patients with cirrhosis and are associated with poor prognosis. There are no studies that analyze the impact of different infectious complications in the mortality of these patients, so we aimed to perform this evaluation. Materials and methods: We performed a case-control study in adult patients with cirrhosis with a follow-up period of one year. We recorded demographic data, prognostic scales, infectious complications and mortality at 30, 90 and 365 days. For the survival analysis, Kaplan-Meyer survival curve was performed and hazard ratios were calculated with 95% confidence intervals by Cox-regression in univariate and multivariate models. For the comparison between groups the Chi squared test, Fisher's exact test and Mann-Whitney U test were performed. Results: We included 500 patients. Median age was 58 years, predominant sex was woman (52%) and the most common infections were urinary tract infections (35%), pneumonia (28.2%) and spontaneous bacterial peritonitis (SBP) (18%). From the patients, 40.4% were CTP score C and median MELD score was 15. In the univariate analysis, infections in general, SBP, pneumonia and central nervous system (CNS) infections had an increased mortality at the three follow up periods, however in the multivariate analysis with the prognostic scales, only pneumonia (HR 2.03, CI 95%[1.06-3.86]) and CNS infections (HR 4.84, CI 95%[1.38-16.93]) remained with increased mortality. Conclusions: Some infectious complications, as pneumonia and CNS infections, increase mortality in hospitalized patients with cirrhosis, regardless of the severity of liver disease.
MeSH term(s)	Aged ; Bacterial Infections/epidemiology ; Case-Control Studies ; Central Nervous System Infections/epidemiology ; Female ; Hospitalization ; Humans ; Infections/epidemiology ; Kaplan-Meier Estimate ; Liver Cirrhosis/epidemiology ; Male ; Middle Aged ; Mortality ; Peritonitis/epidemiology ; Pneumonia/epidemiology ; Proportional Hazards Models ; Retrospective Studies ; Risk Factors ; Severity of Illness Index ; Urinary Tract Infections/epidemiology
Language	English
Publishing date	2020-03-06
Publishing country	Mexico
Document type	Journal Article
ZDB-ID	2188733-0
ISSN	1665-2681
ISSN	1665-2681
DOI	10.1016/j.aohep.2020.02.005
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6221: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Bacterial infections in cirrhosis: Current treatment.

Miranda-Zazueta, Godolfino / León-Garduño, Luis A Ponce de / Aguirre-Valadez, Jonathan / Torre-Delgadillo, Aldo

Annals of hepatology

2019 Volume 19, Issue 3, Page(s) 238–244

Abstract: Bacterial infections frequently cause decompensating events in cirrhotic patients and are also the most common factor identified for the development of acute-on-chronic liver failure (ACLF). The increase in the prevalence of infections caused by ... ...

Abstract	Bacterial infections frequently cause decompensating events in cirrhotic patients and are also the most common factor identified for the development of acute-on-chronic liver failure (ACLF). The increase in the prevalence of infections caused by multidrug-resistant (MDR) microorganisms has resulted in the reduced effectiveness of empiric antimicrobial treatment. We conducted a PubMed search from the last 20 years using the Keywords cirrhosis; multidrug-resistant; infections; diagnosis; treatment; prophylaxis; monitoring; sepsis; nutrition and antibiotic resistant. We made a review about bacterial infections among cirrhotic patients; we mainly focus on the description of diagnostic tools; biomarkers; clinical scores for diagnosis and prognosis also; we made an analysis concerning the monitoring of cirrhotic patients with sepsis and finally made some recommendations about the treatment; prophylaxis and prevention.
MeSH term(s)	Acute-On-Chronic Liver Failure ; Anti-Bacterial Agents/therapeutic use ; Bacteremia/diagnosis ; Bacteremia/drug therapy ; Bacterial Infections/diagnosis ; Bacterial Infections/drug therapy ; Chemoprevention ; Cross Infection/diagnosis ; Cross Infection/drug therapy ; Drug Resistance, Multiple, Bacterial ; Empyema/diagnosis ; Empyema/drug therapy ; Hepatic Encephalopathy ; Hepatorenal Syndrome ; Humans ; Intensive Care Units ; Liver Cirrhosis ; Peritonitis/diagnosis ; Peritonitis/drug therapy ; Peritonitis/prevention & control ; Pneumonia, Bacterial/diagnosis ; Pneumonia, Bacterial/drug therapy ; Sepsis/diagnosis ; Sepsis/drug therapy ; Soft Tissue Infections/diagnosis ; Soft Tissue Infections/drug therapy ; Urinary Tract Infections/diagnosis ; Urinary Tract Infections/drug therapy
Chemical Substances	Anti-Bacterial Agents
Language	English
Publishing date	2019-11-21
Publishing country	Mexico
Document type	Journal Article ; Review
ZDB-ID	2188733-0
ISSN	1665-2681
ISSN	1665-2681
DOI	10.1016/j.aohep.2019.09.011
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6221: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Pharmacologic management of patients with hepatic and pancreatic diseases that involve immunosuppressive therapies. Position statement within the framework of the SARS-CoV-2 (COVID-19) pandemic.

Miranda-Zazueta, G / González-Regueiro, J A / García-Juárez, I / Moctezuma-Velázquez, C / López-Díaz, F J / Pérez-González, B / Uscanga-Domínguez, L F / Peláez-Luna, M

Revista de gastroenterologia de Mexico (English)

2020 Volume 85, Issue 3, Page(s) 312–320

Abstract: The coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus2 (SARS-CoV-2) virus. COVID-19 affected more than 6million persons worldwide in fewer than 4 months, after the report of the first cases in China in ... ...

Title translation	Manejo farmacológico de pacientes con enfermedades hepáticas y pancreáticas que involucran terapias inmunosupresoras. Posicionamiento en el marco de la pandemia de SARS-CoV-2 (COVID-19).
Abstract	The coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus2 (SARS-CoV-2) virus. COVID-19 affected more than 6million persons worldwide in fewer than 4 months, after the report of the first cases in China in December 2019. The relation of the disease caused by SARS-Cov-2 to immunosuppressive treatment used in different gastrointestinal disorders is uncertain, resulting in debate with regard to suspending immunosuppressive therapy to improve infection outcome. Said suspension implies the inherent risk for graft rejection or autoimmune disease exacerbation that can potentially worsen the course of the infection. Based on the presently available evidence, a treatment stance has been established for patients with gastrointestinal diseases that require immunosuppressive therapy.
MeSH term(s)	COVID-19 ; Coronavirus Infections/complications ; Humans ; Immunosuppressive Agents/adverse effects ; Immunosuppressive Agents/therapeutic use ; Liver Diseases/complications ; Liver Diseases/drug therapy ; Liver Transplantation ; Pancreas Transplantation ; Pancreatic Diseases/complications ; Pancreatic Diseases/drug therapy ; Pandemics ; Pneumonia, Viral/complications
Chemical Substances	Immunosuppressive Agents
Keywords	covid19
Language	Spanish
Publishing date	2020-06-17
Document type	Journal Article
ISSN	2255-534X
ISSN (online)	2255-534X
DOI	10.1016/j.rgmx.2020.06.001
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: NAFLD determined by Dallas Steatosis Index is associated with poor outcomes in COVID-19 pneumonia: a cohort study.

Moctezuma-Velázquez, Paulina / Miranda-Zazueta, Godolfino / Ortiz-Brizuela, Edgar / Garay-Mora, Juan Alberto / González-Lara, María Fernanda / Tamez-Torres, Karla Maria / Román-Montes, Carla Marina / Díaz-Mejía, Bruno Alejandro / Pérez-García, Esteban / Villanueva-Reza, Marco / Chapa-Ibargüengoitia, Monica / Uscanga-Domínguez, Luis / Sifuentes-Osornio, José / Ponce-de-León, Alfredo / Kershenobich-Stalnikowitz, David / Mota-Ayala, Blanca / Moctezuma-Velázquez, Carlos

Internal and emergency medicine

2022 Volume 17, Issue 5, Page(s) 1355–1362

Abstract: Coronavirus disease 2019 is a worldwide health challenge. Liver steatosis diagnosis based on imaging studies has been implicated in poor outcomes of COVID-19 pneumonia, but results are inconsistent. The Dallas Steatosis Index (DSI) is an available ... ...

Abstract	Coronavirus disease 2019 is a worldwide health challenge. Liver steatosis diagnosis based on imaging studies has been implicated in poor outcomes of COVID-19 pneumonia, but results are inconsistent. The Dallas Steatosis Index (DSI) is an available calculator developed to identify patients with non-alcoholic fatty liver disease (NAFLD). We hypothesized that it would be associated with in-hospital mortality, intensive care unit admission (ICU), and invasive mechanical ventilation (IMV). We conducted a retrospective cohort study on inpatients with confirmed COVID-19 pneumonia between February 26 and April 11, 2020. We computed the DSI on admission, and patients with high DSI were considered with NAFLD. We employed logistic regression to study the association between NAFLD, mortality, ICU admission, and IMV. We studied the association between liver steatosis on computed tomography (CT) and these outcomes, and also between Metabolic Associated Fatty Liver Disease (MAFLD) based on CT findings and risk factors and the outcomes. 470 patients were included; 359 had NAFLD according to the DSI. They had a higher frequency of type 2 diabetes (31% vs 14%, p < 0.001), obesity (58% vs 14%, p < 0.001), and arterial hypertension (34% vs 22%, p = 0.02). In univariable analysis, NAFLD was associated with mortality, ICU admission, and IMV. Liver steatosis by CT and MAFLD were not associated with any of these outcomes. In multivariable logistic regression, high DSI remained significantly associated with IMV and death. High DSI, which can be easily computed on admission, was associated with IMV and death, and its use to better stratify the prognosis of these patients should be explored. On the other hand, liver steatosis by CT and MAFLD were not associated with poor outcomes.
MeSH term(s)	COVID-19/complications ; Cohort Studies ; Diabetes Mellitus, Type 2/complications ; Humans ; Non-alcoholic Fatty Liver Disease/complications ; Retrospective Studies
Language	English
Publishing date	2022-02-09
Publishing country	Italy
Document type	Journal Article
ZDB-ID	2454173-4
ISSN	1970-9366 ; 1828-0447
ISSN (online)	1970-9366
ISSN	1828-0447
DOI	10.1007/s11739-022-02933-x
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 6673: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Manejo farmacológico de pacientes con enfermedades hepáticas y pancreáticas que involucran terapias inmunosupresoras. Posicionamiento en el marco de la pandemia de SARS-CoV-2 (COVID-19)

Miranda-Zazueta, G. / González-Regueiro, J.A. / García-Juárez, I. / Moctezuma-Velázquez, C. / López-Díaz, F.J. / Pérez-González, B. / Uscanga-Domínguez, L.F. / Peláez-Luna, M.

Revista de Gastroenterología de México

2020 Volume 85, Issue 3, Page(s) 312–320

Keywords	Gastroenterology ; covid19
Language	Spanish
Publisher	Elsevier BV
Publishing country	us
Document type	Article ; Online
ZDB-ID	732082-6
ISSN	0375-0906
ISSN	0375-0906
DOI	10.1016/j.rgmx.2020.06.001
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

In stock of ZB MED Cologne/Königswinter

Zs.B 2057: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Pharmacologic management of patients with hepatic and pancreatic diseases that involve immunosuppressive therapies. Positioning within the framework of the SARS-CoV-2 (COVID-19) pandemic

Miranda-Zazueta, G. / González-Regueiro, J.A. / García-Juárez, I. / Moctezuma-Velázquez, C. / López-Díaz, F.J. / Pérez-González, B. / Uscanga-Domínguez, L.F. / Peláez-Luna, M.

Revista de Gastroenterología de México (English Edition)

2020 Volume 85, Issue 3, Page(s) 312–320

Keywords	covid19
Language	English
Publisher	Elsevier BV
Publishing country	us
Document type	Article ; Online
ISSN	2255-534X
DOI	10.1016/j.rgmxen.2020.06.002
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- Full text online
- Order with fees

Article: Pharmacologic management of patients with hepatic and pancreatic diseases that involve immunosuppressive therapies. Position statement within the framework of the SARS-CoV-2 (COVID-19) pandemic

Miranda-Zazueta, G. / González-Regueiro, J. A. / García-Juárez, I. / Moctezuma-Velázquez, C. / López-Díaz, F. J. / Pérez-González, B. / Uscanga-Domínguez, L. F. / Peláez-Luna, M.

Revista de Gastroenterología de México (English Edition)

Abstract: The coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus COVID-19 affected close to 2 million persons worldwide in fewer than 4 months, after the report of the first cases in China in ... ...

Abstract	The coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus COVID-19 affected close to 2 million persons worldwide in fewer than 4 months, after the report of the first cases in China in December 2019 The relation of the disease caused by SARS-Cov-2 to immunosuppressive treatment used in different gastrointestinal disorders is uncertain, resulting in debate with regard to suspending immunosuppressive therapy to improve infection outcome Said suspension implies the inherent risk for graft rejection or autoimmune disease exacerbation that can potentially worsen the course of the infection Based on the presently available evidence, a treatment stance has been established for patients with gastrointestinal diseases that require immunosuppressive therapy Resumen La enfermedad por coronavirus 2019 (COVID-19) es causada por el virus de Síndrome Respiratorio Agudo Grave - Coronavirus 2 (SARS-CoV-2) COVID 19 afectó cerca de 2 millones de personas en todo el mundo en menos de 4 meses posterior al reporte de los primeros casos en China en diciembre 2019 La relación que guarda la enfermedad por SARS-Cov-2 con el tratamiento inmunosupresor utilizado en diversos trastornos gastrointestinales es incierta, esto genera el debate sobre suspender el tratamiento inmunosupresor para mejorar el pronóstico de la infección, lo cual incluye el riesgo inherente de rechazo de injerto o agudización de enfermedades autoinmunes que potencialmente pudieran agravar el curso de la infección En base a la evidencia disponible se logra establecer una postura de tratamiento en pacientes con enfermedades gastrointestinales que requieren terapia inmunosupresora
Keywords	covid19
Publisher	WHO
Document type	Article
Note	WHO #Covidence: #639894
Database	COVID19

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article: Manejo farmacológico de pacientes con enfermedades hepáticas y pancreáticas que involucran terapias inmunosupresoras. Posicionamiento en el marco de la pandemia de SARS-CoV-2 (COVID-19)./ Manejo farmacológico de pacientes con enfermedades hepáticas y pancreáticas que involucran terapias inmunosupresoras. Posicionamiento en el marco de la pandemia de SARS-CoV-2 (COVID-19)./ Pharmacologic management of patients with hepatic and pancreatic diseases that involve immunosuppressive therapies. Position statement within the framework of the SARS-CoV-2 (COVID-19) pandemic

Miranda-Zazueta, G / González-Regueiro, J A / García-Juárez, I / Moctezuma-Velázquez, C / López-Díaz, F J / Pérez-González, B / Uscanga-Domínguez, L F / Peláez-Luna, M

Rev Gastroenterol Mex

Abstract	The coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus2 (SARS-CoV-2) virus. COVID-19 affected more than 6million persons worldwide in fewer than 4 months, after the report of the first cases in China in December 2019. The relation of the disease caused by SARS-Cov-2 to immunosuppressive treatment used in different gastrointestinal disorders is uncertain, resulting in debate with regard to suspending immunosuppressive therapy to improve infection outcome. Said suspension implies the inherent risk for graft rejection or autoimmune disease exacerbation that can potentially worsen the course of the infection. Based on the presently available evidence, a treatment stance has been established for patients with gastrointestinal diseases that require immunosuppressive therapy.
Keywords	covid19
Publisher	WHO
Document type	Article
Note	WHO #Covidence: #601358
Database	COVID19

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article ; Online: Pharmacologic management of patients with hepatic and pancreatic diseases that involve immunosuppressive therapies. Positioning within the framework of the SARS-CoV-2 (COVID-19) pandemic

G. Miranda-Zazueta / J.A. González-Regueiro / I. García-Juárez / C. Moctezuma-Velázquez / F.J. López-Díaz / B. Pérez-González / L.F. Uscanga-Domínguez / M. Peláez-Luna

Revista de Gastroenterología de México (English Edition), Vol 85, Iss 3, Pp 312-

2020 Volume 320

Abstract: The coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. COVID-19 affected close to 2 million persons worldwide in fewer than 4 months, after the report of the first cases in China in ... ...

Abstract	The coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. COVID-19 affected close to 2 million persons worldwide in fewer than 4 months, after the report of the first cases in China in December 2019. The relation of the disease caused by SARS-Cov-2 to immunosuppressive treatment used in different gastrointestinal disorders is uncertain, resulting in debate with regard to suspending immunosuppressive therapy to improve infection outcome. Said suspension implies the inherent risk for graft rejection or autoimmune disease exacerbation that can potentially worsen the course of the infection. Based on the presently available evidence, a treatment stance has been established for patients with gastrointestinal diseases that require immunosuppressive therapy. Resumen: La enfermedad por coronavirus 2019 (COVID-19) es causada por el virus de Síndrome Respiratorio Agudo Grave - Coronavirus 2 (SARS-CoV-2). COVID 19 afectó cerca de 2 millones de personas en todo el mundo en menos de 4 meses posterior al reporte de los primeros casos en China en diciembre 2019. La relación que guarda la enfermedad por SARS-Cov-2 con el tratamiento inmunosupresor utilizado en diversos trastornos gastrointestinales es incierta, esto genera el debate sobre suspender el tratamiento inmunosupresor para mejorar el pronóstico de la infección, lo cual incluye el riesgo inherente de rechazo de injerto o agudización de enfermedades autoinmunes que potencialmente pudieran agravar el curso de la infección. En base a la evidencia disponible se logra establecer una postura de tratamiento en pacientes con enfermedades gastrointestinales que requieren terapia inmunosupresora.
Keywords	COVID-19 ; Inmunosupresión ; Coronavirus ; Trasplante hepático ; Hepatitis autoinmune ; Diseases of the digestive system. Gastroenterology ; RC799-869 ; covid19
Language	English
Publishing date	2020-07-01T00:00:00Z
Publisher	Elsevier
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Kategorien

Inter-library loan at ZB MED

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED